VYNE Therapeutics Inc.

NasdaqCM:VYNE Stock Report

Market Cap: US$19.0m

VYNE Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VYNE?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders822,9852.47%
Institutions6,472,56019.4%
General Public25,990,87778.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 125.6%.

Top Shareholders

Top 25 shareholders own 21.43% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
3.35%
Access Industries, Inc.
1,116,585US$636.5k0%0.01%
2.84%
T3 Trading Group, LLC
945,000US$538.7k0%0.72%
2.56%
Baker Bros. Advisors LP
851,353US$485.3k0%no data
1.92%
Acadian Asset Management LLC
638,492US$363.9k43%no data
1.76%
Acorn Bioventures
586,572US$334.3k-20.4%0.12%
1.48%
Shay Capital LLC
492,577US$280.8k0%0.05%
1.25%
David Domzalski
416,208US$237.2k-2.96%no data
0.94%
The Vanguard Group, Inc.
314,545US$179.3k65.2%no data
0.87%
Ikarian Capital, LLC
290,000US$165.3k0%0.03%
0.68%
Geode Capital Management, LLC
225,152US$128.3k64.2%no data
0.66%
Two Sigma Investments, LP
220,788US$125.8k0%no data
0.38%
Mutya Harsch
125,905US$71.8k-2.76%no data
0.35%
Iain Stuart
115,239US$65.7k-2.08%no data
0.32%
Boothbay Fund Management, LLC
106,459US$60.7k0%no data
0.31%
Tyler Zeronda
103,795US$59.2k-7.04%no data
0.23%
Bridgeway Capital Management, LLC
76,958US$43.9k0%no data
0.22%
Jane Street Group, LLC
72,356US$41.2k-50.8%no data
0.19%
UBS Asset Management AG
62,761US$35.8k1,030%no data
0.17%
Susquehanna International Group, LLP
57,763US$32.9k-0.09%no data
0.17%
Two Sigma Advisers, LP
56,600US$32.3k0%no data
0.16%
GSA Capital Partners LLP
53,961US$30.8k50.2%no data
0.15%
Patrick LePore
51,472US$29.3k0%no data
0.15%
Staley Capital Advisers, Inc.
51,472US$29.3k0%no data
0.15%
Corsair Capital Management, L.P.
50,000US$28.5k400%no data
0.15%
Rangeley Capital, LLC
50,000US$28.5k0%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/15 02:14
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VYNE Therapeutics Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas TsaoBarclays
Jason Matthew GerberryBofA Global Research
Julian HarrisonBTIG